The Determinants of Sensitivity and Acquired Resistance to Gemcitabine Differ in Non-Small Cell Lung Cancer: A Role of ABCC5 in Gemcitabine Sensitivity

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-06-0025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combination Studies With Gemcitabine in the Treatment of Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Metastatic Non-Small-Cell Lung Cancer and the Use of Gemcitabine During Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2008English

Refractory Non-Small-Cell Lung Cancer Responding to Combination Chemotherapy With Gemcitabine and Cisplatin

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2003English

Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”

Oncologist
Cancer ResearchMedicineOncology
1999English

162P: Molecular Markers in Advanced Non Small Cell Lung Cancer Patients Receiving Gemcitabine & Cisplatin

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Gemcitabine Plus Vinorelbine in Elderly or Unfit Patients With Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2000English

Gemcitabine in Non-Small Cell Lung Cancer (NSCLC): The Evidence of Its Therapeutic Value in Molecular Age

Clinical Medicine Reviews in Oncology
2010English

Pharmacokinetics of Gemcitabine in Non-Small-Cell Lung Cancer Patients: Impact of the 79A>C Cytidine Deaminase Polymorphism

European Journal of Clinical Pharmacology
MedicinePharmacology
2010English

Knockdown of POLA2 Increases Gemcitabine Resistance in Lung Cancer Cells

BMC Genomics
BiotechnologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy